NEW YORK (GenomeWeb News) – Sequencing technology firm PathoGenetix has raised $3.6 million, it said in a regulatory filing.

In the document filed with the US Securities and Exchange Commission on Tuesday, the Woburn, Mass.-based firm said it is targeting $9.1 million in the current offering. The type of securities being offered is in the form of equity. The company did not identify the investors or say how it plans to use the funding.

A company official did not respond to an e-mail requesting comment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.